Impact of probiotic supplementation on mortality of induced 1,2-dimethylhydrazine carcinogenesis in a mouse model

Nutrition

Volumn 26, Issue 7-8, 2010, Pages 779-783

  Liboredo, Juliana Costa ^a   Anastácio, Lucilene Rezende ^a   Mattos, Leonardo Vidal ^a   Nicoli, Jacques Robert ^a   Toulson Davisson Correia, Maria Isabel ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Bacterial translocation; Bifidobacterium animalis var. lactis Bb12; Injury; Lactobacillus delbrueckii UFV H2b20; Mortality; Saccharomyces boulardii, Probiotics; Stress

Indexed keywords

1,2 DIMETHYLHYDRAZINE; DRINKING WATER; PROBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM ANIMALIS; CARCINOGENESIS; CONTROLLED STUDY; DEATH; LACTOBACILLUS DELBRUECKII; LIVER; MALE; MESENTERY LYMPH NODE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII; SPLEEN; SUPPLEMENTATION; TREATMENT DURATION;

ANIMALS; BIFIDOBACTERIUM; DIETARY SUPPLEMENTS; DIMETHYLHYDRAZINES; DISEASE MODELS, ANIMAL; LACTOBACILLUS; MALE; MICE; NEOPLASMS; PROBIOTICS; SACCHAROMYCES;

ANIMALIA; BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM ANIMALIS; LACTOBACILLUS DELBRUECKII; MUS; SACCHAROMYCES BOULARDII;

EID: 77953754315     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2010.01.008     Document Type: Article

References (57)

1. " Guidelines for the Evaluation of Probiotics in Food." 2002, FAO/WHO Expert Consultation, Ontario (Canada), London.
2. Donohue D.C., Salminen S. Safety of probiotic bacteria. Asia Pacific J Clin Nutr 1996, 5:25-28.
3. Bengmark S., Gianotti L. Nutritional support to prevent and treat multiple organ failure. World J Surg 1996, 20:474-481.
4. Shortt C. The probiotic century: historical and current perspectives. Trends Food Sci Technol 1999, 10:411-417.
5. Martins F.S., Rodrigues A.C.P., Tiago F.C.P., Penna F.J., Rosa C.A., Arantes R.M.E., et al. Saccharomyces cerevisiae strain 905 reduces the translocation of Salmonella enterica serotype Typhimurium and stimulates the immune system in gnotobiotic and conventional mice. J Med Microbiol 2007, 56:352-359.
6. Ishibashi N., Yamazaki S. Probiotics and safety. Am J Clin Nutr 2001, 73(suppl):465S-470S.
7. Rautio M., Jousimies-Somer H., Kauma H., Pietarinen I., Saxelin M., Tynkkynen S., et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L rhamnosus strain GG. Clin Infect Dis 1999, 28:1159-1160.
8. Land M.H., Rouster-Stevens K., Woods C.R., Cannon M.L., Cnota J., Shetty A.K. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005, 115:178-181.
9. Viggiano M., Badetti C., Bernini V., Garabedian M., Manelli J.C. Saccharomyces boulardii fungemia in a patient with severe burns. Ann Fr Anesth Reanim 1995, 14:356-358.
10. Rijnders B.J., Van W.E., Verwaest C., Peetermans W.E. Saccharomyces fungemia complicating Saccharomyces boulardii treatment in a non-immunocompromised host. Intensive Care Med 2000, 26:825.
11. Lherm T., Monet C., Nougiere B., Soulier M., Larbi D., Gall C.L., et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002, 28:797-801.
12. Riquelme A.J., Calvo M.A., Guzman A.M., Depix M.S., García P., Pérez C., et al. Saccharomyces cerevisiae Fungemia after Saccharomyces boulardii treatment in immunocompromisedpatients. J Clin Gastroenterol 2003, 36:41-43.
13. Cassone M., Serra P., Mondello F., Girolamo A., Scafetti S., Pistella E., et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003, 41:5340-5343.
14. Lestin F., Pertschy A., Rimek D. Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities. Dtsch Med Wochenschr 2003, 128:2531-2533.
15. Boyle R.B., Robins-Browne R.M., Tang M.L.K. Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr 2006, 83:1256-1264.
16. Surawicz C.M. Probiotics, antibiotic-associated diarrhea and Clostridium difficile diarrhea in humans. Best Pract Res Clin Gastroenterol 2003, 17:775-783.
17. Born P., Lersch C., Zimmerhackl B., Claassen M. The Saccharomyces boulardii therapy of HIV-associated diarrhea. Dtsch Med Wochenschr 1993, 118:765.
18. Bleichner G., Blehaut H., Mentec H., Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med 1997, 23:517-523.
19. Scarpignato C., Rampal P. Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. Chemotherapy 1995, 41:48-81.
20. Marteau P.R. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001, 73:430-436.
21. Reid G. Probiotic agents to protect the urogenital tract against infection. American J Clin Nutr 2001, 73:437-443.
22. Guslandi M., Mezzi G., Sorghi M., Testoni P.A. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000, 45:1462-1464.
23. Guslandi M., Giollo P., Testoni P.A. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003, 15:697-698.
24. Shanahan F. Probiotics and inflammatory bowel disease: Is there a scientific rationale?. Inflamm Bowel Dis 2000, 6:107-115.
25. Shanahan F. Probiotics and inflammatory bowel disease: from fads to fantasy to acts and future. Br.. J. Nutr 2000, 88:5-9.
26. Tuohy K.M., Probert H.M., Smejkal C.W., Gibson G.R. Using probiotics and prebiotics to improve gut health. Drug Disc Today 2003, 8:692-700.
27. Cummings J.H., Macfarlane G.T., Macfarlane S. Intestinal bacteria and ulcerative colitis. Curr Issues Intest Microbiol 2003, 4:9-20.
28. Bai A.P., Ouyang Q. Probiotics and inflammatory bowel diseases. Postgrad Med J 2006, 82:376-382.
29. Vrese M., Stegelmann A., Richter B., Fenselau S., Laue C., Schrezenmeir U. Probiotics-compensation for lactase insufficiency. Am J Clin Nutr 2001, 73:421-429.
30. Gilliland S.E., Walker D.K. Factors to consider when selecting a culture of Lactobacillus acidophilus as a dietary adjunct to produce a hypocholesterolemic effect in humans. J Dairy Sci 1990, 73:905-911.
31. Taranto M.P., Medici M., Perdigon G., Holgado A.P.R., Valdez G.F. Evidence for hypocholesterolemic effect of Lactobacillus reuteri in hypercholesterolemic mice. J Dairy Sci 1998, 81:2336-2340.
32. Mackay A.D., Taylor M.B., Kibbler C.C., Hamilton-Miller J.M. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999, 5:290-292.
33. Kunz A.N., Noel J.M., Fairchok M.P. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 2004, 38:457-458.
34. DeGroote M.A., Frank D.N., Dowell E., Glode M.P., Pace N.R. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005, 24:278-280.
35. Oggioni M.R., Pozzi G., Valensin P.E., Galieni P., Bigazzi C. Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis. J Clin Microbiol 1998, 36:325-326.
36. Bassetti S., Frei R., Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998, 105:71-72.
37. Corrêa N.B., Peret Filho L.A., Penna F.J., Lima F.M., Nicoli J.R. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol 2005, 39:385-389.
38. Surawicz C.M. Probiotics, antibiotic-associated diarrhea and Clostridium difficile diarrhea in humans. Best Pract Res Clin Gastroenterol 2003, 17:775-783.
39. Elmer G.W., Mcfarland L.V. Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol Clin North Am 2001, 30:837-854.
40. Born P., Lersch C., Zimmerhackl B., Claassen M. The Saccharomyces boulardii therapy of HIV-associated diarrhea. Dtsch Med Wochenschr 1993, 118:765.
41. Bleichner G., Blehaut H., Mentec H., Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med 1997, 23:517-523.
42. Scarpignato C., Rampal P. Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. Chemotherapy 1995, 41:48-58.
43. Berg R.D., Garlington A.W. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun 1979, 23:403-411.
44. Berg R.D. Translocation of microbes from the intestinal tract. Medical importance of the normal microflora 1999, 338-370. Kluwer Academic Publishers, London. G.W. Tannock (Ed.).
45. Berg R.D. The indigenous gastrointestinal microflora. Trends Microbiol 1996, 4:430-435.
46. Morehouse J.L., Specian R.D., Stewart J.J., Berg R.D. Translocation of indigenous bacteria from the gastrointestinal tract of mice after oral ricinoleic acid treatment. Gastroenterology 1986, 91:673-682.
47. Berg R.D., Wommack E., Deitch E.A. Immunosuppression and intestinal bacterial overgrowth synergistically promote bacterial translocation. Arch Surg 1988, 123:1359-1364.
48. Mannick J.A., Rodrick M.L., Lederer J.A. The immunologic response to injury. J Am Coll Surg 2001, 193:237-244.
49. Broaddus R.R., Wargovich M.J., Castro G.A. Early stages of 1,2-dimethylhydrazine-induced colon carcinogenesis suppress immune-regulated ion transport of mouse distal colon. Cancer Res 1994, 54:5930-5936.
50. Soler A.P., Miller R.D., Laughlin K.V., Carp N.Z., Klurfeld D.M., Mullin J.M. Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis 1999, 20:1425-1431.
51. Berg R.D. Bacterial translocation from the intestines. Exp Anim 1985, 34:1-16.
52. Van Leeuwen P.A.M., Boermeester M.A., Houdijk A.P.J. Ferwerda ChC, Cuesta MA, Meyer S. Clinical significance of translocation. Gut 1994, 35:28-34.
53. Alexander J.W., Boyce S.T., Babcock G.F., Gianotti L., Peck M.D., Dunn D.L., et al. The process of microbial translocation. Ann Surg 1990, 212:496-510.
54. Mattar A.F., Drongowski R.A., Coran A.G., Harmon C.M. Effect of probiotics on enterocyte bacterial translocation in vitro. Pediatr Surg Int 2001, 17:265-268.
55. Eizaguirre I., Garcia Urkia N., Asensio A.B., Zubillaga I., Zubillaga P., Vidales C., et al. Probiotic supplementation reduces the risk of bacterial translocation in experimental short bowel syndrome. J Pediatr Surg 2002, 37:699-702.
56. Berg R., Bernasconi P., Fowler D., Gautreaux M. Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. J Infect Dis 1993, 168:1314-1318.
57. Gianotti L., Alexander J.W., Pyles T., Fukushima R.M. Arginine-supplemented diets improve survival in gut-derived sepsis and peritonitis by modulating bacterial clearance. The role of nitric oxide. Ann Surg 1993, 217:644-654.